Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

Commitments and Contingencies

Commitments and Contingencies

9.Commitments and Contingencies

Drug Supplier Project Plan – The amounts paid for manufacture of the Company’s Grb2 drug substance, prexigebersen, Bcl‑2 drug substance and BP1002 drug product that have not been expensed total $0.7 million and are carried on the balance sheet as of June 30, 2019 as Prepaid Drug Product for Testing (See Note 3). Total commitments for the Company’s drug supplier project plan are $1.9 million as of June 30, 2019, comprised of $1.4 million to the manufacturer of prexigebersen and BP1002 drug product, $0.4 million for manufacture of our Grb2 and Bcl‑2 drug substances, and $0.1 million for manufacturing development. We expect to incur $1.1 million of these commitments over the next 12 months.